keyword
MENU ▼
Read by QxMD icon Read
search

Fibrosis AND linagliptin

keyword
https://www.readbyqxmd.com/read/27513960/linagliptin-ameliorates-methylglyoxal-induced-peritoneal-fibrosis-in-mice
#1
Takuo Nagai, Shigehiro Doi, Ayumu Nakashima, Taisuke Irifuku, Kensuke Sasaki, Toshinori Ueno, Takao Masaki
Recent studies have reported increases of methylglyoxal (MGO) in peritoneal dialysis patients, and that MGO-mediated inflammation plays an important role in the development of peritoneal fibrosis through production of transforming growth factor-β1 (TGF-β1). Linagliptin, a dipeptidyl peptidase-4 inhibitor, exerts anti-inflammatory effects independent of blood glucose levels. In this study, we examined whether linagliptin suppresses MGO-induced peritoneal fibrosis in mice. Male C57/BL6 mice were divided into three groups: control, MGO injection plus saline, and MGO injection plus linagliptin (n = 6 per group)...
2016: PloS One
https://www.readbyqxmd.com/read/27475229/stromal-cell-derived-factor-1-is-upregulated-by%C3%A2-dipeptidyl-peptidase-4-inhibition-and-has%C3%A2-protective-roles-in-progressive-diabetic%C3%A2-nephropathy
#2
Satoru Takashima, Hiroki Fujita, Hiromi Fujishima, Tatsunori Shimizu, Takehiro Sato, Tsukasa Morii, Katsushi Tsukiyama, Takuma Narita, Takamune Takahashi, Daniel J Drucker, Yutaka Seino, Yuichiro Yamada
The role of stromal cell-derived factor-1 (SDF-1) in the pathogenesis of diabetic nephropathy and its modification by dipeptidyl peptidase-4 (DPP-4) inhibition are uncertain. Therefore, we studied this independent of glucagon-like peptide-1 receptor (GLP-1R) signaling using two Akita diabetic mouse models, the diabetic-resistant C57BL/6-Akita and diabetic-prone KK/Ta-Akita. Increased SDF-1 expression was found in glomerular podocytes and distal nephrons in the diabetic-prone mice, but not in kidneys from diabetic-resistant mice...
October 2016: Kidney International
https://www.readbyqxmd.com/read/27462372/empagliflozin-an-sglt2-inhibitor-alone-or-in-combination-with-linagliptin-a-dpp-4-inhibitor-prevents-steatohepatitis-in-a-novel-mouse-model-of-non-alcoholic-steatohepatitis-and-diabetes
#3
Teruo Jojima, Takanori Tomotsune, Toshie Iijima, Kazumi Akimoto, Kunihiro Suzuki, Yoshimasa Aso
BACKGROUND: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are new oral antidiabetic drugs that reduce hyperglycemia by promoting urinary glucose excretion. Glycosuria produced by SGLT2 inhibitors is associated with weight loss, mainly due to reduced fat volume. We investigated the effects of empagliflozin (selective SGLT2 inhibitor) and linagliptin (DPP-4 inhibitor) on steatohepatitis and fibrosis in a mouse model of non-alcoholic steatohepatitis (NASH) with diabetes. METHODS: A novel NASH model was generated by administration of streptozotocin to C57BL/6J mice at 2 days old, with a high-fat diet from 4 weeks...
2016: Diabetology & Metabolic Syndrome
https://www.readbyqxmd.com/read/27391040/dipeptidyl-peptidase-4-inhibition-with-linagliptin-prevents-western-diet-induced-vascular-abnormalities-in-female-mice
#4
Camila Manrique, Javad Habibi, Annayya R Aroor, James R Sowers, Guanghong Jia, Melvin R Hayden, Mona Garro, Luis A Martinez-Lemus, Francisco I Ramirez-Perez, Thomas Klein, Gerald A Meininger, Vincent G DeMarco
BACKGROUND: Vascular stiffening, a risk factor for cardiovascular disease, is accelerated, particularly in women with obesity and type 2 diabetes. Preclinical evidence suggests that dipeptidylpeptidase-4 (DPP-4) inhibitors may have cardiovascular benefits independent of glycemic lowering effects. Recent studies show that consumption of a western diet (WD) high in fat and simple sugars induces aortic stiffening in female C57BL/6J mice in advance of increasing blood pressure. The aims of this study were to determine whether administration of the DPP-4 inhibitor, linagliptin (LGT), prevents the development of aortic and endothelial stiffness induced by a WD in female mice...
2016: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/27083282/the-dipeptidyl-peptidase-inhibitor-linagliptin-and-the-angiotensin-ii-receptor-blocker-telmisartan-show-renal-benefit-by-different-pathways-in-rats-with-5-6-nephrectomy
#5
Oleg Tsuprykov, Ryotaro Ando, Christoph Reichetzeder, Karoline von Websky, Viktoriia Antonenko, Yuliya Sharkovska, Lyubov Chaykovska, Jan Rahnenführer, Ahmed A Hasan, Harald Tammen, Markus Alter, Thomas Klein, Seiji Ueda, Sho-Ichi Yamagishi, Seiya Okuda, Berthold Hocher
Dipeptidyl peptidase (DPP)-4 inhibitors delay chronic kidney disease (CKD) progression in experimental diabetic nephropathy in a glucose-independent manner. Here we compared the effects of the DPP-4 inhibitor linagliptin versus telmisartan in preventing CKD progression in non-diabetic rats with 5/6 nephrectomy. Animals were allocated to 1 of 4 groups: sham operated plus placebo; 5/6 nephrectomy plus placebo; 5/6 nephrectomy plus linagliptin; and 5/6 nephrectomy plus telmisartan. Interstitial fibrosis was significantly decreased by 48% with linagliptin but a non-significant 24% with telmisartan versus placebo...
May 2016: Kidney International
https://www.readbyqxmd.com/read/26826382/linagliptin-but-not-sitagliptin-inhibited-transforming-growth-factor-%C3%AE-2-induced-endothelial-dpp-4-activity-and-the-endothelial-mesenchymal-transition
#6
COMPARATIVE STUDY
Sen Shi, Keizo Kanasaki, Daisuke Koya
Dipeptidyl peptidase (DPP)-4 plays an important role in endothelial cell biology. We have shown that the DPP-4 inhibitor Linagliptin can inhibit the endothelial-mesenchymal transition (EndMT) and ameliorate diabetic kidney fibrosis associated with the suppression of DPP-4 protein levels via the induction of miR-29. The current study demonstrated that such effects of Linagliptin on endothelial cell profibrotic programs were drug-specific but not class effects. In the cell-free system, both Linagliptin and Sitagliptin inhibited recombinant DPP-4 activity in a concentration-dependent manner...
February 26, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/26802469/renoprotective-effect-of-dpp-4-inhibitors-against-free-fatty-acid-bound-albumin-induced-renal-proximal-tubular-cell-injury
#7
Yuki Tanaka, Shinji Kume, Masami Chin-Kanasaki, Hisazumi Araki, Shin-ichi Araki, Satoshi Ugi, Takeshi Sugaya, Takashi Uzu, Hiroshi Maegawa
Dipeptidyl peptidase (DPP)-4 inhibitors, a new class of antidiabetic agent, have recently been suggested to exert pleiotropic effects beyond glucose lowering. Renal prognosis in patients with diabetic nephropathy depends on the severity of tubulointerstitial injury induced by massive proteinuria. We thus examined the renoprotective effect of DPP-4 inhibitors on inflammation in cultured mouse proximal tubular cells stimulated with free fatty acid (FFA)-bound albumin. Linagliptin and higher concentrations of sitagliptin, vildagliptin, and alogliptin all inhibited FFA-bound albumin-induced increases in mRNA expression of MCP-1 in cultured mouse proximal tubular cells...
February 12, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/26323066/evidence-for-antifibrotic-incretin-independent-effects-of-the-dpp-4-inhibitor-linagliptin
#8
COMMENT
Michael Zeisberg, Elisabeth M Zeisberg
Among gliptins, linagliptin is unique, because decreased glomerular filtration rate does not require dose reduction. Linagliptin was originally developed to lower blood glucose by inhibiting dipeptidyl peptidase-4 (DPP-4). However, DPP-4 has numerous additional substrates, and thus gliptins possess a vast range of additional off-target effects. Shi et al. report that linagliptin directly targets interaction of DPP-4 with integrin β1, preventing endothelial-mesenchymal transition and ultimately renal fibrosis, providing additional rationale for use of linagliptin in diabetic nephropathy...
September 2015: Kidney International
https://www.readbyqxmd.com/read/25994830/preservation-of-glucagon-like-peptide-1-level-attenuates-angiotensin-ii-induced-tissue-fibrosis-by-altering-at1-at-2-receptor-expression-and-angiotensin-converting-enzyme-2-activity-in-rat-heart
#9
Li-Hui Zhang, Xue-Fen Pang, Feng Bai, Ning-Ping Wang, Ahmed Ijaz Shah, Robert J McKallip, Xue-Wen Li, Xiong Wang, Zhi-Qing Zhao
PURPOSE: The glucagon-like peptide-1 (GLP-1) has been shown to exert cardioprotective effects in animals and patients. This study tests the hypothesis that preservation of GLP-1 by the GLP-1 receptor agonist liraglutide or the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is associated with a reduction of angiotensin (Ang) II-induced cardiac fibrosis. METHODS AND RESULTS: Sprague-Dawley rats were subjected to Ang II (500 ng/kg/min) infusion using osmotic minipumps for 4 weeks...
June 2015: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/25830763/interactions-of-dpp-4-and-integrin-%C3%AE-1-influences-endothelial-to-mesenchymal-transition
#10
Sen Shi, Swayam Prakash Srivastava, Megumi Kanasaki, Jianhua He, Munehiro Kitada, Takako Nagai, Kyoko Nitta, Susumu Takagi, Keizo Kanasaki, Daisuke Koya
Integrin β1 and dipeptidyl peptidase (DPP)-4 play roles in endothelial cell biology. Vascular endothelial growth factor (VEGF)-A inhibits endothelial-to-mesenchymal transition (EndMT) through VEGF-R2, but through VEGF-R1 promotes EndMT by reducing the bioavailability of VEGF-A. Here we tested whether DPP-4-integrin β1 interactions have a role in EndMT in the renal fibrosis of diabetic nephropathy. In streptozotocin-induced fibrotic kidneys in diabetic CD-1 mice, levels of endothelial DPP-4, integrin β1, and phospho-integrin β1 were all higher and associated with plasma cystatin C elevation...
September 2015: Kidney International
https://www.readbyqxmd.com/read/25768281/a-dpp-4-inhibitor-suppresses-fibrosis-and-inflammation-on-experimental-autoimmune-myocarditis-in-mice
#11
Hiroyuki Hirakawa, Hirofumi Zempo, Masahito Ogawa, Ryo Watanabe, Jun-Ichi Suzuki, Hiroshi Akazawa, Issei Komuro, Mitsuaki Isobe
Myocarditis is a critical inflammatory disorder which causes life-threatening conditions. No specific or effective treatment has been established. DPP-4 inhibitors have salutary effects not only on type 2 diabetes but also on certain cardiovascular diseases. However, the role of a DPP-4 inhibitor on myocarditis has not been investigated. To clarify the effects of a DPP-4 inhibitor on myocarditis, we used an experimental autoimmune myocarditis (EAM) model in Balb/c mice. EAM mice were assigned to the following groups: EAM mice group treated with a DPP-4 inhibitor (linagliptin) (n = 19) and those untreated (n = 22)...
2015: PloS One
https://www.readbyqxmd.com/read/25471116/dpp-4-inhibitor-linagliptin-ameliorates-cardiovascular-injury-in-salt-sensitive-hypertensive-rats-independently-of-blood-glucose-and-blood-pressure
#12
Nobutaka Koibuchi, Yu Hasegawa, Tetsuji Katayama, Kensuke Toyama, Ken Uekawa, Daisuke Sueta, Hiroaki Kusaka, MingJie Ma, Takashi Nakagawa, Bowen Lin, Shokei Kim-Mitsuyama
BACKGROUND: It remains to be elucidated whether dipeptidylpeptidase-4 (DPP-4) inhibitor can ameliorate cardiovascular injury in salt-sensitive hypertension. The present study was undertaken to test our hypothesis that linagliptin, a DPP-4 inhibitor, administration initiated after onset of hypertension and cardiac hypertrophy can ameliorate cardiovascular injury in Dahl salt-sensitive hypertensive rats (DS rats). METHODS: High-salt loaded DS rats with established hypertension and cardiac hypertrophy were divided into two groups, and were orally given (1) vehicle or (2) linagliptin (3 mg/kg/day) once a day for 4 weeks, and cardiovascular protective effects of linagliptin in DS rats were evaluated...
2014: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/25226384/hibiscus-sabdariffa-polyphenols-alleviate-insulin-resistance-and-renal-epithelial-to-mesenchymal-transition-a-novel-action-mechanism-mediated-by-type-4-dipeptidyl-peptidase
#13
Chiung-Huei Peng, Yi-Sun Yang, Kuei-Chuan Chan, Chau-Jong Wang, Mu-Lin Chen, Chien-Ning Huang
The epithelial to mesenchymal transition (EMT) is important in renal fibrosis. Ser307 phosphorylation of insulin receptor substrate-1 (IRS-1 (S307)) is a hallmark of insulin resistance. We report that polyphenol extracts of Hibiscus sabdariffa (HPE) ameliorate diabetic nephropathy and EMT. Recently it has been observed that type 4 dipeptidyl peptidase (DPP-4) inhibitor linagliptin is effective for treating type 2 diabetes and albuminuria. We investigated if DPP-4 and insulin resistance are involved in renal EMT and explored the role of HPE...
October 8, 2014: Journal of Agricultural and Food Chemistry
https://www.readbyqxmd.com/read/24895991/dipeptidyl-peptidase-4-inhibition-improves-left-ventricular-function-in-chronic-kidney-disease
#14
Kim A Connelly, Bridgit B Bowskill, Suzanne L Advani, Kerri Thai, Li-Hao Chen, M Golam Kabir, Richard E Gilbert, Andrew Advani
PURPOSE: Heart failure with preserved ejection fraction (HFpEF) is a common comorbidity in people with chronic kidney disease (CKD) for which no evidence-based treatment currently exists. Recently, a group of anti-hyperglycemic agents used in the treatment of Type 2 diabetes, termed incretin-based therapies, have come under scrutiny for their putative glucose-independent effects on cardiac function. In the present study, the actions of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of incretin-based therapy in preventing HFpEF induced by chronic renal impairment were investigated...
2014: Clinical and Investigative Medicine. Médecine Clinique et Experimentale
https://www.readbyqxmd.com/read/24574044/linagliptin-mediated-dpp-4-inhibition-ameliorates-kidney-fibrosis-in-streptozotocin-induced-diabetic-mice-by-inhibiting-endothelial-to-mesenchymal-transition-in-a-therapeutic-regimen
#15
Keizo Kanasaki, Sen Shi, Megumi Kanasaki, Jianhua He, Takako Nagai, Yuka Nakamura, Yasuhito Ishigaki, Munehiro Kitada, Swayam Prakash Srivastava, Daisuke Koya
Kidney fibrosis is the final common pathway of all progressive chronic kidney diseases, of which diabetic nephropathy is the leading cause. Endothelial-to-mesenchymal transition (EndMT) has emerged as one of the most important origins of matrix-producing fibroblasts. Dipeptidyl peptidase-4 (DPP-4) inhibitors have been introduced into the market as antidiabetes drugs. Here, we found that the DPP-4 inhibitor linagliptin ameliorated kidney fibrosis in diabetic mice without altering the blood glucose levels associated with the inhibition of EndMT and the restoration of microRNA 29s...
June 2014: Diabetes
https://www.readbyqxmd.com/read/24077249/effects-of-telmisartan-and-linagliptin-when-used-in-combination-on-blood-pressure-and-oxidative-stress-in-rats-with-2-kidney-1-clip-hypertension
#16
Lyubov Chaykovska, Markus L Alter, Karoline von Websky, Margarete Hohmann, Oleg Tsuprykov, Christoph Reichetzeder, Barbara Kutil, Robin Kraft, Thomas Klein, Berthold Hocher
OBJECTIVE: To investigate the effects of linagliptin alone and in combination with the angiotensin II receptor blocker (ARB), telmisartan on blood pressure (BP), kidney function, heart morphology and oxidative stress in rats with renovascular hypertension. METHODS: Fifty-seven male Wistar rats underwent unilateral surgical stenosis of the renal artery [2-kidney-1-clip (2k1c) method]. Animals were randomly divided into four treatment groups (n = 14-18 per group) receiving: telmisartan (10 mg/kg per day in drinking water), linagliptin (89 ppm in chow), combination (linagliptin 89 ppm + telmisartan 10 mg/kg per day) or placebo...
November 2013: Journal of Hypertension
https://www.readbyqxmd.com/read/24048504/linagliptin-alleviates-hepatic-steatosis-and-inflammation-in-a-mouse-model-of-non-alcoholic-steatohepatitis
#17
Thomas Klein, Masato Fujii, Jan Sandel, Yuichiro Shibazaki, Kyoko Wakamatsu, Michael Mark, Hiroyuki Yoneyama
Non-alcoholic steatohepatitis (NASH) is a primary cause of cirrhosis and hepatocellular carcinoma. Dipeptidyl peptidase (DPP)-4 inhibitors are established therapies for type 2 diabetes and although DPP-4 inhibitors can reduce hepatic steatosis, their impact on local inflammation and fibrosis in NASH remains unknown. Using two different experimental treatment regimens (4- and 2-week treatments) in streptozotocin-treated neonatal mice on a high-fat diet, we show that the DPP-4 inhibitor linagliptin (10 and 30 mg/kg) significantly attenuated the NAS score from 4...
September 2014: Medical Molecular Morphology
https://www.readbyqxmd.com/read/23653460/dipeptidylpeptidase-inhibition-is-associated-with-improvement-in-blood-pressure-and-diastolic-function-in-insulin-resistant-male-zucker-obese-rats
#18
Annayya R Aroor, James R Sowers, Shawn B Bender, Ravi Nistala, Mona Garro, Irina Mugerfeld, Melvin R Hayden, Megan S Johnson, Muhammad Salam, Adam Whaley-Connell, Vincent G Demarco
Diastolic dysfunction is a prognosticator for future cardiovascular events that demonstrates a strong correlation with obesity. Pharmacological inhibition of dipeptidylpeptidase-4 (DPP-4) to increase the bioavailability of glucagon-like peptide-1 is an emerging therapy for control of glycemia in type 2 diabetes patients. Accumulating evidence suggests that glucagon-like peptide-1 has insulin-independent actions in cardiovascular tissue. However, it is not known whether DPP-4 inhibition improves obesity-related diastolic dysfunction...
July 2013: Endocrinology
https://www.readbyqxmd.com/read/22125632/effects-of-dpp-4-inhibitors-on-the-heart-in-a-rat-model-of-uremic-cardiomyopathy
#19
Lyubov Chaykovska, Karoline von Websky, Jan Rahnenführer, Markus Alter, Susi Heiden, Holger Fuchs, Frank Runge, Thomas Klein, Berthold Hocher
BACKGROUND: Uremic cardiomyopathy contributes substantially to mortality in chronic kidney disease (CKD) patients. Glucagon-like peptide-1 (GLP-1) may improve cardiac function, but is mainly degraded by dipeptidyl peptidase-4 (DPP-4). METHODOLOGY/PRINCIPAL FINDINGS: In a rat model of chronic renal failure, 5/6-nephrectomized [5/6N] rats were treated orally with DPP-4 inhibitors (linagliptin, sitagliptin, alogliptin) or placebo once daily for 4 days from 8 weeks after surgery, to identify the most appropriate treatment for cardiac dysfunction associated with CKD...
2011: PloS One
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"